Braveheart Bio, Inc. is a San Francisco, California-headquartered clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, with the Company's lead product candidate BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor (CMI), being developed for both obstructive HCM (oHCM) and non-obstructive HCM (nHCM). The Company completed its initial public offering in early August 2026 (offering 18,750,000 shares with a cornerstone investor indication of up to $75 million), with the net proceeds together with existing cash and cash equivalents intended to fund the advancement of BHB-1893 through completion of Phase 3 clinical trials in both oHCM and nHCM, including research and development personnel and overhead costs, with the remainder for working capital and general corporate purposes. As of March 31, 2026, the Company had an accumulated deficit of $80.3 million, with substantially all operating losses resulting from research and development programs and general and administrative costs, and the pro forma net tangible book value as of March 31, 2026 was $71.5 million ($1.66 per share).
The investment thesis rests on three variables. The BHB-1893 Phase 3 execution trajectory is the load-bearing clinical variable, with the dual Phase 3 programs in oHCM and nHCM representing a broad label ambition that differentiates from the first-generation CMIs (mavacamten/Camzyos and aficamten/Myqorzo) which are approved only for oHCM, and the strategic intent is to execute the global Phase 3 programs on timeline and demonstrate the next-generation profile (speed of onset, depth of gradient response, systolic safety, reversibility, reduced prescribing complexity). The cash runway and capital efficiency is the load-bearing financial variable, with the IPO proceeds plus existing cash and cash equivalents designed to fund the Company through completion of both Phase 3 trials, and the strategic intent is to maintain the capital discipline that avoids a mid-program financing overhang. The competitive differentiation against first-generation CMIs is the load-bearing commercial variable, with BHB-1893's preclinical profile suggesting advantages in speed of onset, gradient response, systolic safety, reversibility, and prescribing simplicity that could drive adoption in both oHCM and nHCM, and the strategic intent is to translate the preclinical differentiation into clinical and commercial differentiation.